期刊
PANCREATOLOGY
卷 15, 期 3, 页码 295-301出版社
ELSEVIER
DOI: 10.1016/j.pan.2015.02.008
关键词
Fluorescence-guided surgery; Pancreatic cancer; Patient derived orthotopic xenograft; Neoadjuvant chemotherapy; CEA; PDOX
资金
- National Cancer Institute [CA132971, 142669]
- JSPS [26830081, 26462070, 24592009]
- Grants-in-Aid for Scientific Research [24592009, 26462070, 26830081] Funding Source: KAKEN
Background: The aim of this study is to determine the efficacy of neoadjuvant chemotherapy (NAC) with gemcitabine (GEM) in combination with fluorescence-guided surgery (FGS) on a pancreatic cancer patient derived orthotopic xenograft (PDOX) model. Methods: A PDOX model was established from a CEA-positive tumor from a patient who had undergone a pancreaticoduodenectomy for pancreatic adenocarcinoma. Mice were randomized to 4 groups: bright light surgery (BLS) only; BLS + NAC; FGS only; and FGS + NAC. An anti-CEA antibody conjugated to DyLight 650 was administered intravenously via the tail vein of mice with a pancreatic cancer PDOX 24 h before surgery. Results: The PDOX was clearly labeled with fluorophore-conjugated anti-CEA antibody. Only one out of 8 mice had local recurrence in the FGS only group and zero out of 8 mice had local recurrence in the FGS + NAC which was significantly lower than BLS only or BLS + NAC mice, where local disease recurred in 6 out of 8 mice in each treatment group (p = 0.041 and p = 0.007, respectively). NAC did not significantly reduce recurrence rates when combined with either FGS or BLS. Conclusion: These results indicate that FGS can significantly reduce local recurrence compared to BLS in pancreatic cancer resistant to NAC. Copyright (C) 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据